Clinical Program
Phase 1: Oncology

Our lead drug candidate SDX-7320 is a polymer conjugate of a novel fumagillin derivative being developed for patients suffering from cancer. Fumagillin-class drugs inhibit the enzyme methionine aminopeptidase type 2 (MetAP2), an enzyme shown to be important in many tumor types. SDX-7320 is in Phase 1 clinical development for solid tumors.

In human trials, fumagillin-class drugs have shown signs of clinical activity including a complete response in metastatic cervical cancer, significant weight loss in morbidly obese patients and decreased cardio-metabolic parameters (triglycerides and LDL levels) in obese patients.

Our polymer drug conjugates are designed to be stable in circulation. Release of the active fumagillol derivative drug is presumed to occur inside cells, reducing circulating levels of the released fumagillol derivative, and thereby lowering the potential for toxicity.  

One of the known side effects of fumagillin-based small molecules is central neurotoxicity, which halted the clinical development of TNP-470 in cancer. Due to the high molecular weight of our polymer drug conjugate, SDX-7320 should not cross the blood-brain barrier potentially reducing the risk of central nervous system toxicities. Additionally the intrinsic properties of the polymer drug conjugate change the distribution of the released active drug enabling lower doses with potentially greater clinical activity.

These properties are expected to provide a better therapeutic index when compared to traditional small molecule drug candidates.

SDX-7320* is in clinical development, and has demonstrated broad biologic activity in animal models of cancer and metabolic disease.

 

*This compound is currently in development and is not approved by the FDA (or any other regulatory authority) for clinical use.